Biodesix Inc
BDSX0.381USD
+0.017+4.76%
Market hours （ET）Quotes delayed by 15 min
55.72MMarket Cap
LossP/E TTM
More Details of Biodesix Inc Company
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
Company Info
Ticker SymbolBDSX
Company nameBiodesix Inc
IPO dateOct 28, 2020
CEOMr. Scott Hutton
Number of employees273
Security typeOrdinary Share
Fiscal year-endOct 28
Address919 West Dillon Road
CityLOUISVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code80027
Phone13034170500
Websitehttps://www.biodesix.com/
Ticker SymbolBDSX
IPO dateOct 28, 2020
CEOMr. Scott Hutton
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
7.44M
+0.31%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
3.06M
--
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
363.50K
+7.82%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
357.54K
--
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
248.63K
+0.88%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
139.05K
+0.73%
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Independent Director
Independent Director
108.14K
+32.25%
Mr. Lawrence T. (Lair) Kennedy, Jr.
Mr. Lawrence T. (Lair) Kennedy, Jr.
Independent Director
Independent Director
--
--
Mr. Scott Hutton
Mr. Scott Hutton
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
7.44M
+0.31%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
3.06M
--
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
363.50K
+7.82%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
357.54K
--
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
248.63K
+0.88%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
139.05K
+0.73%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
16.32M
90.86%
Development Services
1.64M
9.14%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
16.32M
90.86%
Development Services
1.64M
9.14%
Shareholding Stats
Updated: Thu, Jul 31
Updated: Thu, Jul 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schuler (Jack W)
24.51%
Kennedy (Lawrence T Jr.)
17.37%
Telemark Asset Management, LLC
5.65%
Patience (John)
5.08%
Bryn Mawr Trust Company
4.16%
Other
43.24%
Shareholders
Shareholders
Proportion
Schuler (Jack W)
24.51%
Kennedy (Lawrence T Jr.)
17.37%
Telemark Asset Management, LLC
5.65%
Patience (John)
5.08%
Bryn Mawr Trust Company
4.16%
Other
43.24%
Shareholder Types
Shareholders
Proportion
Individual Investor
50.77%
Investment Advisor
14.38%
Hedge Fund
10.44%
Bank and Trust
4.16%
Investment Advisor/Hedge Fund
3.58%
Corporation
1.49%
Private Equity
1.48%
Research Firm
0.80%
Venture Capital
0.07%
Other
12.83%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
120
127.74M
87.16%
-11.27M
2025Q1
120
125.21M
85.46%
-14.47M
2024Q4
117
129.55M
88.77%
+1.50M
2024Q3
108
133.06M
91.48%
+18.48M
2024Q2
113
122.73M
87.79%
+36.49M
2024Q1
129
78.49M
81.85%
-3.28M
2023Q4
126
82.91M
102.14%
+18.03M
2023Q3
132
83.04M
103.87%
+18.19M
2023Q2
137
65.80M
84.63%
+503.77K
2023Q1
140
65.48M
84.42%
+858.57K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schuler (Jack W)
35.92M
24.51%
+4.72M
+15.14%
May 19, 2025
Kennedy (Lawrence T Jr.)
25.45M
17.37%
+106.20K
+0.42%
Mar 03, 2025
Telemark Asset Management, LLC
8.28M
5.65%
--
--
Mar 31, 2025
Patience (John)
7.44M
5.08%
+22.87K
+0.31%
Jun 30, 2025
Bryn Mawr Trust Company
6.10M
4.16%
--
--
Mar 31, 2025
Birchview Capital, LP
5.74M
3.91%
--
--
Mar 31, 2025
SilverArc Capital Management, LLC
4.10M
2.8%
-233.88K
-5.40%
Mar 31, 2025
Monashee Investment Management, LLC
4.05M
2.76%
+549.12K
+15.69%
Mar 31, 2025
The Vanguard Group, Inc.
3.82M
2.61%
--
--
Mar 31, 2025
Opaleye Management Inc.
3.23M
2.2%
-240.00K
-6.93%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
